Summary of Oseltamivir versus placebo for preventing influenza in adults *

Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. BMJ. 2014 Apr 9;348:g2545. doi: 10.1136/bmj.g2545. Review.

Outcomes	Relative effect (95% CI)	Absolute Risk difference (95% CI)	Clinical implications
Symptomatic influenza in adult prophylaxis of individuals	**RR 0.45** (0.30 to 0.67)	3.1% (1.8 to 3.9)	For every 100 persons treated prophylactically with oseltamivir there would be 3 people less with a laboratory diagnosis of influenza and symptoms
Symptomatic influenza in household prophylaxis	**RR 0.2** (0.09 to 0.44)	13.6% (9.5 to 15.5)	For every 100 persons treated prophylactically in households with oseltamivir there would be 13 to 14 people less with a laboratory diagnosis of influenza and symptoms
Asymptomatic influenza in adult prophylaxis of individuals	**RR 0.78 (0.49 to 1.24)**	0.72% (-0.79 to 1.68)	For every 100 persons treated prophylactically with oseltamivir there would be no effect on the number of people with a laboratory diagnosis of influenza and no symptoms
Asymptomatic lab confirmed influenza in household prophylaxis	**RR 1.14 (0.39 to 3.33)**	-0.42% (-6.99 to 1.83)	For every 100 persons treated prophylactically in households with oseltamivir there would be no effect on the number of people with a laboratory diagnosis of influenza and no symptoms
Hospitalisation in adult prophylaxis (safety population)	**RR 1.14 (0.66 to 1.94)**	-0.2% (-1.5 to 0.6)	For every 100 persons treated prophylactically with oseltamivir there would be no effect on hospitalisation
Adverse events: psychiatric body systems in adult prophylaxis (all events on- and off-treatment)	**RR 1.80** (1.05 to 3.08)	-1.1% (-2.8 to -0.07)	For every 100 persons treated prophylactically 1 person would report a serious psychiatric adverse event
Adverse events: headache in adult prophylaxis (on-treatment)	**RR 1.18** (1.05 to 1.33)	-3.2% (-5.8 to -0.9	For every 100 persons treated prophylactically 3 people would report headache during treatment as an adverse event
Adverse events: nausea in adult prophylaxis (on-treatment)	**RR 1.96** (1.2 to 3.2)	-4.2% (-9.5 to -0.9)	For every 100 persons treated prophylactically 4 people would report nausea during treatment as an adverse event
Adverse events: vomiting in adult prophylaxis (on-treatment)	**RR 1.91** (0.7 to 5.22)	-0.95% (-4.4 to 0.3)	For every 100 persons treated prophylactically 1 person would report vomiting during treatment as an adverse event

Prepared by Igho Onakpoya, Carl heneghan and Tom Jefferson on the 16th January 2015

*Results should be checked against the original results before using this summary to inform individual patient decisions